Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease

Ray L. Watts, Kelly E. Lyons, Rajesh Pahwa, Kapil Sethi, Matthew Stern, Robert A. Hauser, Warren Olanow, Alex M. Gray, Bryan Adams, Nancy L. Earl

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Levodopa-induced dyskinesia can result in significant functional disability and reduced quality of life in patients with Parkinson's disease (PD). The goal of this study was to determine if the addition of once-daily ropinirole 24-hour prolonged-release (n = 104) in PD patients not optimally controlled with levodopa after up to 3 years of therapy with less than 600 mg/d delays the onset of dyskinesia compared with increasing doses of levodopa (n = 104). During the study, 3% of the ropinirole prolonged-release group (mean dose 10 mg/d) and 17% of the levodopa group (mean additional dose 284 mg/d) developed dyskinesia (P < 0.001). There were no significant differences in change in Unified Parkinson's Disease Rating Scale activities of daily living or motor scores, suggesting comparable efficacy between the two treatments. Adverse events were comparable in the two groups with nausea, dizziness, insomnia, back pain, arthralgia, somnolence, fatigue, and pain most commonly reported. Ropinirole prolonged-release delayed the onset of dyskinesia with comparable efficacy to increased doses of levodopa in early PD patients not optimally controlled with levodopa.

Original languageEnglish (US)
Pages (from-to)858-866
Number of pages9
JournalMovement Disorders
Volume25
Issue number7
DOIs
StatePublished - May 15 2010

Fingerprint

Dyskinesias
Levodopa
Parkinson Disease
Arthralgia
Sleep Initiation and Maintenance Disorders
Dizziness
Back Pain
Activities of Daily Living
Nausea
Fatigue
ropinirole
Quality of Life
Pain
Therapeutics

Keywords

  • Dyskinesia
  • Levodopa
  • Parkinson's disease
  • Ropinirole prolonged-release

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Watts, R. L., Lyons, K. E., Pahwa, R., Sethi, K., Stern, M., Hauser, R. A., ... Earl, N. L. (2010). Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease. Movement Disorders, 25(7), 858-866. https://doi.org/10.1002/mds.22890

Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease. / Watts, Ray L.; Lyons, Kelly E.; Pahwa, Rajesh; Sethi, Kapil; Stern, Matthew; Hauser, Robert A.; Olanow, Warren; Gray, Alex M.; Adams, Bryan; Earl, Nancy L.

In: Movement Disorders, Vol. 25, No. 7, 15.05.2010, p. 858-866.

Research output: Contribution to journalArticle

Watts, RL, Lyons, KE, Pahwa, R, Sethi, K, Stern, M, Hauser, RA, Olanow, W, Gray, AM, Adams, B & Earl, NL 2010, 'Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease', Movement Disorders, vol. 25, no. 7, pp. 858-866. https://doi.org/10.1002/mds.22890
Watts, Ray L. ; Lyons, Kelly E. ; Pahwa, Rajesh ; Sethi, Kapil ; Stern, Matthew ; Hauser, Robert A. ; Olanow, Warren ; Gray, Alex M. ; Adams, Bryan ; Earl, Nancy L. / Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease. In: Movement Disorders. 2010 ; Vol. 25, No. 7. pp. 858-866.
@article{93cd05bfe29945bfb4a35f0aeae59309,
title = "Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease",
abstract = "Levodopa-induced dyskinesia can result in significant functional disability and reduced quality of life in patients with Parkinson's disease (PD). The goal of this study was to determine if the addition of once-daily ropinirole 24-hour prolonged-release (n = 104) in PD patients not optimally controlled with levodopa after up to 3 years of therapy with less than 600 mg/d delays the onset of dyskinesia compared with increasing doses of levodopa (n = 104). During the study, 3{\%} of the ropinirole prolonged-release group (mean dose 10 mg/d) and 17{\%} of the levodopa group (mean additional dose 284 mg/d) developed dyskinesia (P < 0.001). There were no significant differences in change in Unified Parkinson's Disease Rating Scale activities of daily living or motor scores, suggesting comparable efficacy between the two treatments. Adverse events were comparable in the two groups with nausea, dizziness, insomnia, back pain, arthralgia, somnolence, fatigue, and pain most commonly reported. Ropinirole prolonged-release delayed the onset of dyskinesia with comparable efficacy to increased doses of levodopa in early PD patients not optimally controlled with levodopa.",
keywords = "Dyskinesia, Levodopa, Parkinson's disease, Ropinirole prolonged-release",
author = "Watts, {Ray L.} and Lyons, {Kelly E.} and Rajesh Pahwa and Kapil Sethi and Matthew Stern and Hauser, {Robert A.} and Warren Olanow and Gray, {Alex M.} and Bryan Adams and Earl, {Nancy L.}",
year = "2010",
month = "5",
day = "15",
doi = "10.1002/mds.22890",
language = "English (US)",
volume = "25",
pages = "858--866",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease

AU - Watts, Ray L.

AU - Lyons, Kelly E.

AU - Pahwa, Rajesh

AU - Sethi, Kapil

AU - Stern, Matthew

AU - Hauser, Robert A.

AU - Olanow, Warren

AU - Gray, Alex M.

AU - Adams, Bryan

AU - Earl, Nancy L.

PY - 2010/5/15

Y1 - 2010/5/15

N2 - Levodopa-induced dyskinesia can result in significant functional disability and reduced quality of life in patients with Parkinson's disease (PD). The goal of this study was to determine if the addition of once-daily ropinirole 24-hour prolonged-release (n = 104) in PD patients not optimally controlled with levodopa after up to 3 years of therapy with less than 600 mg/d delays the onset of dyskinesia compared with increasing doses of levodopa (n = 104). During the study, 3% of the ropinirole prolonged-release group (mean dose 10 mg/d) and 17% of the levodopa group (mean additional dose 284 mg/d) developed dyskinesia (P < 0.001). There were no significant differences in change in Unified Parkinson's Disease Rating Scale activities of daily living or motor scores, suggesting comparable efficacy between the two treatments. Adverse events were comparable in the two groups with nausea, dizziness, insomnia, back pain, arthralgia, somnolence, fatigue, and pain most commonly reported. Ropinirole prolonged-release delayed the onset of dyskinesia with comparable efficacy to increased doses of levodopa in early PD patients not optimally controlled with levodopa.

AB - Levodopa-induced dyskinesia can result in significant functional disability and reduced quality of life in patients with Parkinson's disease (PD). The goal of this study was to determine if the addition of once-daily ropinirole 24-hour prolonged-release (n = 104) in PD patients not optimally controlled with levodopa after up to 3 years of therapy with less than 600 mg/d delays the onset of dyskinesia compared with increasing doses of levodopa (n = 104). During the study, 3% of the ropinirole prolonged-release group (mean dose 10 mg/d) and 17% of the levodopa group (mean additional dose 284 mg/d) developed dyskinesia (P < 0.001). There were no significant differences in change in Unified Parkinson's Disease Rating Scale activities of daily living or motor scores, suggesting comparable efficacy between the two treatments. Adverse events were comparable in the two groups with nausea, dizziness, insomnia, back pain, arthralgia, somnolence, fatigue, and pain most commonly reported. Ropinirole prolonged-release delayed the onset of dyskinesia with comparable efficacy to increased doses of levodopa in early PD patients not optimally controlled with levodopa.

KW - Dyskinesia

KW - Levodopa

KW - Parkinson's disease

KW - Ropinirole prolonged-release

UR - http://www.scopus.com/inward/record.url?scp=77951941921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951941921&partnerID=8YFLogxK

U2 - 10.1002/mds.22890

DO - 10.1002/mds.22890

M3 - Article

C2 - 20461803

AN - SCOPUS:77951941921

VL - 25

SP - 858

EP - 866

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 7

ER -